153 related articles for article (PubMed ID: 34550682)
1. Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations.
Wang Z; Cai J; Ren J; Chen Y; Wu Y; Cheng J; Jia K; Huang F; Cheng Z; Sheng T; Song S; Heng H; Zhu Y; Tang W; Li H; Lu T; Chen Y; Lu S
J Med Chem; 2021 Oct; 64(19):14664-14701. PubMed ID: 34550682
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
3. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
4. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
5. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-(4-aminophenyl)-6-phenylisoxazolo[3,4-b]pyridine-3-amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia.
Wang QX; Wang YB; Sha JK; Zhou H; Liu JC; Wu JZ; Tong ZJ; Cai J; Chen ZJ; Zhang CQ; Zheng XR; Wang JJ; Wang XL; Xue X; Yu YC; Ding N; Leng XJ; Dai WC; Sun SL; Chang L; Li NG; Shi ZH
Drug Dev Res; 2023 Apr; 84(2):296-311. PubMed ID: 36644989
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N
Gucký T; Řezníčková E; Radošová Muchová T; Jorda R; Klejová Z; Malínková V; Berka K; Bazgier V; Ajani H; Lepšík M; Divoký V; Kryštof V
J Med Chem; 2018 May; 61(9):3855-3869. PubMed ID: 29672049
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
10. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.
Heng H; Zhi Y; Yuan H; Wang Z; Li H; Wang S; Tian J; Liu H; Chen Y; Lu T; Ran T; Lu S
Eur J Med Chem; 2019 Feb; 163():195-206. PubMed ID: 30508668
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
13. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
14. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
15. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
19. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
20. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
